BACKGROUND AND OBJECTIVES: Mounting evidence suggests that 1,25-dihydroxyvitamin D prevents the progression of chronic kidney disease (CKD). It is not clear whether "nutritional" forms of vitamin D affect GFR. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We tested whether serum 25-hydroxyvitamin D concentration (25(OH)D), a measure of total vitamin D intake from cutaneous synthesis and dietary consumption, is associated with loss of estimated GFR among 1705 older adults with predominantly normal baseline kidney function participating in the Cardiovascular Health Study. Baseline 25(OH)D was measured by HPLC-tandem mass spectrometry. GFR was estimated at baseline and 4 years later using the CKD-EPI formula, with rapid GFR loss defined as 12 ml/min per 1.73 m(2) or more over 4 years. RESULTS: Rapid GFR loss was observed for 207 participants (12%). Each 10 ng/ml lower 25(OH)D was associated with a 25% greater risk of rapid GFR loss (95% confidence interval [CI] 5%, 49%, P = 0.01), adjusting for potential confounding characteristics. Compared with 25(OH)D ≥30 ng/ml, 25(OH)D concentrations 15 to 29 ng/ml and <15 ng/ml were associated with 29% (95% CI -13%, 91%) and 68% (95% CI 1%, 177%) greater adjusted risks of rapid GFR loss, respectively. Magnitudes of association were largest among participants with diabetes. RESULTS: were similar evaluating a composite outcome of rapid GFR loss, end stage renal disease, and death. Conclusions Insufficient 25(OH)D may be a modifiable risk factor for early GFR loss. We recommend clinical trials to determine whether vitamin D supplementation prevents the development and progression of CKD.
BACKGROUND AND OBJECTIVES: Mounting evidence suggests that 1,25-dihydroxyvitamin D prevents the progression of chronic kidney disease (CKD). It is not clear whether "nutritional" forms of vitamin D affect GFR. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We tested whether serum 25-hydroxyvitamin D concentration (25(OH)D), a measure of total vitamin D intake from cutaneous synthesis and dietary consumption, is associated with loss of estimated GFR among 1705 older adults with predominantly normal baseline kidney function participating in the Cardiovascular Health Study. Baseline 25(OH)D was measured by HPLC-tandem mass spectrometry. GFR was estimated at baseline and 4 years later using the CKD-EPI formula, with rapid GFR loss defined as 12 ml/min per 1.73 m(2) or more over 4 years. RESULTS: Rapid GFR loss was observed for 207 participants (12%). Each 10 ng/ml lower 25(OH)D was associated with a 25% greater risk of rapid GFR loss (95% confidence interval [CI] 5%, 49%, P = 0.01), adjusting for potential confounding characteristics. Compared with 25(OH)D ≥30 ng/ml, 25(OH)D concentrations 15 to 29 ng/ml and <15 ng/ml were associated with 29% (95% CI -13%, 91%) and 68% (95% CI 1%, 177%) greater adjusted risks of rapid GFR loss, respectively. Magnitudes of association were largest among participants with diabetes. RESULTS: were similar evaluating a composite outcome of rapid GFR loss, end stage renal disease, and death. Conclusions Insufficient 25(OH)D may be a modifiable risk factor for early GFR loss. We recommend clinical trials to determine whether vitamin D supplementation prevents the development and progression of CKD.
Authors: Ian H de Boer; Bryan Kestenbaum; Abigail B Shoben; Erin D Michos; Mark J Sarnak; David S Siscovick Journal: J Am Soc Nephrol Date: 2009-05-14 Impact factor: 10.121
Authors: Daniel Zehnder; Marcus Quinkler; Kevin S Eardley; Rosemary Bland; Julia Lepenies; Susan V Hughes; Neil T Raymond; Alexander J Howie; Paul Cockwell; Paul M Stewart; Martin Hewison Journal: Kidney Int Date: 2008-09-10 Impact factor: 10.612
Authors: Yiting Wang; Eric J Jacobs; Marjorie L McCullough; Carmen Rodriguez; Michael J Thun; Eugenia E Calle; W Dana Flanders Journal: Am J Epidemiol Date: 2009-04-30 Impact factor: 4.897
Authors: Pooneh Alborzi; Nina A Patel; Carla Peterson; Jennifer E Bills; Dagim M Bekele; Zerihun Bunaye; Robert P Light; Rajiv Agarwal Journal: Hypertension Date: 2008-07-07 Impact factor: 10.190
Authors: Zhongyi Zhang; Yan Zhang; Gang Ning; Dilip K Deb; Juan Kong; Yan Chun Li Journal: Proc Natl Acad Sci U S A Date: 2008-10-06 Impact factor: 11.205
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Dena E Rifkin; Michael G Shlipak; Ronit Katz; Linda F Fried; David Siscovick; Michel Chonchol; Anne B Newman; Mark J Sarnak Journal: Arch Intern Med Date: 2008-11-10
Authors: Ian H de Boer; Ronit Katz; Jie J Cao; Linda F Fried; Bryan Kestenbaum; Ken Mukamal; Dena E Rifkin; Mark J Sarnak; Michael G Shlipak; David S Siscovick Journal: Diabetes Care Date: 2009-07-08 Impact factor: 19.112
Authors: Anand Vaidya; Bei Sun; Carol Larson; John P Forman; Jonathan S Williams Journal: J Clin Endocrinol Metab Date: 2012-04-26 Impact factor: 5.958
Authors: Idris Guessous; William McClellan; David Kleinbaum; Viola Vaccarino; Henry Hugues; Olivier Boulat; Pedro Marques-Vidal; Fred Paccaud; Jean-Marc Theler; Jean-Michel Gaspoz; Michel Burnier; Gérard Waeber; Peter Vollenweider; Murielle Bochud Journal: Clin J Am Soc Nephrol Date: 2015-04-21 Impact factor: 8.237
Authors: Jessica Kendrick; Alfred K Cheung; James S Kaufman; Tom Greene; William L Roberts; Gerard Smits; Michel Chonchol Journal: Am J Kidney Dis Date: 2012-05-22 Impact factor: 8.860
Authors: Adrienne Tin; Long Zhang; Michelle M Estrella; Andy Hoofnagle; Casey M Rebholz; Todd T Brown; Frank J Palella; Mallory D Witt; Lisa P Jacobson; Lawrence A Kingsley; Alison G Abraham Journal: AIDS Res Hum Retroviruses Date: 2017-09-05 Impact factor: 2.205
Authors: Ian H de Boer; Leila R Zelnick; Julie Lin; Debra Schaumberg; Lu Wang; John Ruzinski; Georgina Friedenberg; Julie Duszlak; Vadim Y Bubes; Andrew N Hoofnagle; Ravi Thadhani; Robert J Glynn; Julie E Buring; Howard D Sesso; JoAnn E Manson Journal: Contemp Clin Trials Date: 2018-09-30 Impact factor: 2.226